Predictive factors for time to remission and recurrence in patients treated for acute mania: Health outcomes of manic episodes (HOME) study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 2, 2008, Pages 114-119

  Kora, Kaan ^a   Saylan, Mete ^b,f   Akkaya, Cengiz ^c   Karamustafalioglu, Nesrin ^d   Tomruk, Nesrin ^d   Yasan, Aziz ^e   Oral, Timucin ^d  

^a MARMARA UNIVERSITY   (Turkey)

^b ELI LILLY AND COMPANY   (United States)

^c ULUDAG UNIVERSITY   (Turkey)

^d Bakirkoy Mental and Neurological Disease Hospital   (Turkey)

^e Kalp ve Damar Cerrahisi Klini i   (Turkey)

^f NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; DIAZEPAM; HALOPERIDOL; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZUCLOPENTHIXOL;

ACUTE DISEASE; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MIXED MANIA AND DEPRESSION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PREDICTION; RECURRENT DISEASE; REMISSION; TURKEY (REPUBLIC);

EID: 45749093445     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v10n0205     Document Type: Article

References (29)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000;61(suppl 13):38-41
3. Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. J Affect Disord 2001;67(1-3):257-265
4. Baldessarini RJ, Tondo L, Hennen J, et al. Is lithium still worth using? an update of selected recent research. Harv Rev Psychiatry 2002;10:59-75
5. Mensink GJ, Slooff CJ. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand 2004;109:405-419
6. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA 1994;271:918-924
7. Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001;10:661-671
8. Yatham LN, Kusumakar V, Calabrese JR, et al. Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-283
9. Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 2002;63(suppl 3):10-14
10. Calabrese JR, Shelton MD, Rapport DJ, et al. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002;63 (suppl 3):5-9
11. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-1154
12. Sajatovic M, Brescan DW, Perez DE, et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001;62:728-732
13. Coryell W, Endicott J, Maser JD, et al. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. J Affect Disord 1995;33:201-206
14. Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000;61(suppl 9):23-30
15. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107
16. Bromet EJ, Finch SJ, Carlson GA, et al. Time to remission and relapse after the first hospital admission in severe bipolar disorder. Soc Psychiatry Psychiatr Epidemiol 2005;40:106-113
17. Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry Suppl 2001;41:S191-S194
18. Krabbendam L, Myin-Germeys I, De Graaf R, et al. Dimensions of depression, mania, and psychosis in the general population. Psychol Med 2004;34:1117-1186
19. Storosum JG, Fouwels A, Gispen-de Wied CC, et al. How real are patients in placebo-controlled studies of acute manic episode? Eur Neuropsychopharmacol 2004;14:319-323
20. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73(3):159-171
21. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-435
22. Karadag F, Oral T, Yalcin FA, et al. Young Mani Derecelendirme Olceginin Turkiye'de gecerlilik ve guvenilirligi [Reliability and Validity of Turkish Translation of Young Mania Rating Scale]. Turk Psikiyatri Derg 2002;13:107-114
23. Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63(2):120-125
24. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20(1):29-42
25. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
26. Kessing LV. Subtypes of manic episodes according to ICD-10-prediction of time to remission and risk of relapse. J Affect Disord 2004;81(3):279-285
27. Kessing LV, Mortensen PB. Recovery from episodes during the course of affective disorder: a case-register study. Acta Psychiatr Scand 1999;100(4):279-287
28. Saka MC, Ozer S, Ulusahin A. Bipolar bozukluk bir yillik izlem calismasi [Bipolar disorder: one year follow up]. Turk Psikiyatri Derg 2001;12:282-292
29. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Br J Psychiatry 2004;185:372-377